Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia.

Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2024 Jan-Feb

filter terms:

The lower, the better" is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas. Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Citation

Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Tiziana Sampietro. Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2024 Jan-Feb;36(1):35-37